South Africa has begun a three-year rollout of Lenacapavir, a long-acting injection used for HIV prevention [1].
The initiative represents a significant shift in public health strategy by moving away from daily oral medication. This transition could increase adherence rates and reduce new infections across the country's most vulnerable populations [2].
President Cyril Ramaphosa announced the plan in late May 2026 and said that the drug offers hope in the fight against HIV/AIDS [3]. The medical treatment requires administration only twice a year [4]. Health officials aim to reach a target population of more than 3 million South Africans through the rollout [5].
The South African Health Minister said that Lenacapavir is a turning point in the fight against HIV [6]. The government intends to use the tool to strengthen the country's long-term response strategy [2].
However, the scale of the rollout faces potential obstacles. While some reports indicate the drug is now available, other data suggests the process remains dependent on limited doses and consistent funding [7, 8].
Concerns regarding international support have also surfaced. A health policy analyst said that U.S. aid cuts could slow the impact of this promising tool [9]. These funding gaps may create discrepancies between the government's goals and the actual availability of the injections in clinics [8].
“"This offers hope in the fight against HIV/AIDS."”
The shift toward long-acting injectables like Lenacapavir addresses the primary barrier to HIV prevention: the difficulty of maintaining a daily medication regimen. By reducing the frequency of doses to two per year, South Africa aims to stabilize its epidemic response. However, the reliance on external funding and the threat of U.S. aid cuts suggest that the biological success of the drug may be hindered by geopolitical and economic volatility.
